Your browser doesn't support javascript.
loading
EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells.
Mallmann-Gottschalk, Nina; Sax, Yvonne; Kimmig, Rainer; Lang, Stephan; Brandau, Sven.
Afiliação
  • Mallmann-Gottschalk N; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany. nina.mallmann-gottschalk@uk-essen.de.
  • Sax Y; Department of Otorhinolaryngology, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany. nina.mallmann-gottschalk@uk-essen.de.
  • Kimmig R; Department of Otorhinolaryngology, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany. Yvonne.Sax@uk-essen.de.
  • Lang S; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany. rainer.kimmig@uk-essen.de.
  • Brandau S; Department of Otorhinolaryngology, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany. stephan.lang@uk-essen.de.
Int J Mol Sci ; 20(19)2019 Sep 22.
Article em En | MEDLINE | ID: mdl-31546690
ABSTRACT
The adverse prognosis of most patients with ovarian cancer is related to recurrent disease caused by resistance to chemotherapeutic and targeted therapeutics. Besides their direct activity against tumor cells, monoclonal antibodies and tyrosine kinase inhibitors (TKIs) also influence the antitumoral activity of immune cells, which has important implications for the design of immunotherapies. In this preclinical study, we treated different ovarian cancer cell lines with anti-epidermal growth factor receptor (EGFR) TKIs and co-incubated them with natural killer (NK) cells. We studied treatment-related structural and functional changes on tumor and immune cells in the presence of the anti-EGFR antibody cetuximab and investigated NK-mediated antitumoral activity. We show that long-term exposure of ovarian cancer cells to TKIs leads to reduced responsiveness of intrinsically sensitive cancer cells over time. Inversely, neither long-term treatment with TKIs nor cetuximab could overcome the intrinsic resistance of certain ovarian cancer cells to anti-EGFR agents. Remarkably, tumor cells pretreated with anti-EGFR TKIs showed increased sensitivity towards NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). In contrast, the cytokine secretion of NK cells was reduced by TKI sensitization. Our data suggest that sensitization of tumor cells by anti-EGFR TKIs differentially modulates interactions with NK cells. These data have important implications for the design of chemo-immuno combination therapies in this tumor entity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Células Matadoras Naturais / Inibidores de Proteínas Quinases Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Células Matadoras Naturais / Inibidores de Proteínas Quinases Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article